Therefore, our results strongly support the synergy of tafasitamab plus mCHEMO combination in directly reducing DLBCL cell viability by both enhancing intracellular concentrations of chemotherapeutic drugs and affecting phosphorylation of most proteins involved in the Akt/mTOR signaling pathway, which play a fundamental role in controlling lymphoma cell growth and survival35 and downregulating the MYC gene expression. The gene discussed is MYC; the disease is lymphoma.